Hypoxia induces CD133 expression in human lung cancer cells by up-regulation of OCT3/4 and SOX2

International Journal of Oncology

Volumn 40, Issue 1, 2012, Pages 71-79

  Iida, Hajime ^a,b   Suzuki, Mitsuhiro ^a   Goitsuka, Ryo ^b   Ueno, Hikaru ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b TOKYO UNIVERSITY OF SCIENCE   (Japan)

Author keywords

Cancer stem cell; CD133; Gene expression; Hypoxia; Lung cancer

Indexed keywords

CD133 ANTIGEN; CIS ACTING ELEMENT; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN GATA; PROTEIN RUNT; TESTIS DETERMINING FACTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ETS; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; BINDING SITE; CANCER CELL; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENE LOCUS; HUMAN; HUMAN TISSUE; HYPOXIA; LUNG CANCER; PRIORITY JOURNAL; PROMOTER REGION; UPREGULATION;

ANTIGENS, CD; BASE SEQUENCE; BINDING SITES; CELL HYPOXIA; CELL LINE, TUMOR; GLYCOPROTEINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LUNG NEOPLASMS; MOLECULAR SEQUENCE DATA; OCTAMER TRANSCRIPTION FACTOR-3; ORGANIC CATION TRANSPORT PROTEINS; PEPTIDES; PROMOTER REGIONS, GENETIC; SOXB1 TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 84455174511     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1207     Document Type: Article

References (42)

1. Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature 414: 105-111, 2001. (Pubitemid 33041634)
2. Shackleton M, Quintana E, Fearon ER and Morrison SJ: Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 138: 822-829, 2009.
3. Lapidot T, Sirard C, Vormoor J, et al: A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367: 645-648, 1994. (Pubitemid 24067706)
4. Dou J, Pan M, Wen P, et al: Isolation and identification of cancer stem-like cells from murine melanoma cell lines. Cell Mol Immunol 4: 467-472, 2007.
5. Singh SK, Clarke ID, Terasaki M, et al: Identification of a cancer stem cell in human brain tumors. Cancer Res 63: 5821-5828, 2003. (Pubitemid 37187480)
6. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988, 2003. (Pubitemid 36418143)
7. Monroe MM, Anderson EC, Clayburgh DR and Wong MH: Cancer stem cells in head and neck squamous cell carcinoma. J Oncol 2011: doi 762780, 2011.
8. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al: Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115, 2007. (Pubitemid 46067311)
9. Dick JE: Acute myeloid leukemia stem cells. Ann NY Acad Sci 1044: 1-5, 2005.
10. O'Brien CA, Pollett A, Gallinger S and Dick JE: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445: 106-110, 2007. (Pubitemid 46067310)
11. Weigmann A, Corbeil D, Hellwig A and Huttner WB: Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells. Proc Natl Acad Sci USA 94: 12425-12430, 1997. (Pubitemid 27492544)
12. Miraglia S, Godfrey W, Yin AH, et al: A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 90: 5013-5021, 1997.
13. Yin AH, Miraglia S, Zanjani ED, et al: AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90: 5002-5012, 1997. (Pubitemid 28007217)
14. Monzani E, Facchetti F, Galmozzi E, et al: Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 43: 935-946, 2007.
15. Tirino V, Desiderio V, d'Aquino R, et al: Detection and characterization of CD133+ cancer stem cells in human solid tumours. PLoS One 3: e3469, 2008.
16. Ma S, Chan KW, Hu L, et al: Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 132: 2542-2556, 2007.
17. Shmelkov SV, Meeus S, Moussazadeh N, et al: Cytokine preconditioning promotes codifferentiation of human fetal liver CD133+ stem cells into angiomyogenic tissue. Circulation 111: 1175-1183, 2005. (Pubitemid 40365480)
18. Todaro M, Alea MP, Di Stefano AB, et al: Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 1: 389-402, 2007. (Pubitemid 47506537)
19. + ovarian cancer cells. Oncogene 28: 209-218, 2009.
20. Bertolini G, Roz L, Perego P, et al: Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA 106: 16281-16286, 2009.
21. Beier D, Hau P, Proescholdt M, et al: CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 67: 4010-4015, 2007. (Pubitemid 46815044)
22. - metastatic colon cancer cells initiate tumors. J Clin Invest 118: 2111-2120, 2008.
23. Shmelkov SV, Jun L, St Clair R, et al: Alternative promoters regulate transcription of the gene that encodes stem cell surface protein AC133. Blood 103: 2055-2061, 2004. (Pubitemid 38326220)
24. - subpopulations of A549 and H446 cells contain cancer-initiating cells. Cancer Sci 100: 1040-1046, 2009.
25. Tirino V, Camerlingo R, Franco R, et al: The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Eur J Cardiothorac Surg 36: 446-453, 2009.
26. Heddleston JM, Li Z, McLendon RE, Hjelmeland AB and Rich J N: The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 8: 3274-3284, 2009.
27. + human glioblastoma cells in vitro. Mol Cancer Res 7: 489-497, 2009.
28. Mohyeldin A, Garzón-Muvdi T and Quiñones-Hinojosa A: Oxygen in stem cell biology: a critical component of the stem cell niche. Cell Stem Cell 7: 150-161, 2010.
29. Suzuki M, Yamada T, Kihara-Negishi F, et al: Site-specific DNA methylation by a complex of PU.1 and Dnmt3a/b. Oncogene 25: 2477-2488, 2006.
30. Salnikov AV, Gladkich J, Moldenhauer G, Volm M, Mattern J and Herr I: CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients. Int J Cancer 126: 950-958, 2010.
31. Rankin EB and Giaccia AJ: The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 15: 678-685, 2008. (Pubitemid 351405072)
32. Covello KL, Kehler J, Yu H, et al: HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev 20: 557-570, 2006. (Pubitemid 43345322)
33. Niwa H: Molecular mechanism to maintain stem cell renewal of ES cells. Cell Struct Funct 26: 137-148, 2001.
34. Li F, Zeng H and Ying K: The combination of stem cell markers CD133 and ABCG2 predicts relapse in stage I non-small cell lung carcinomas. Med Oncol (In press).
35. Li Z, Bao S, Wu Q, et al: Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 15: 501-513, 2009.
36. Kemper K, Sprick MR, De Bree M, et al: The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res 70: 719-729, 2010.
37. Tabu K, Kimura T, Sasai K, et al: Analysis of an alternative human CD133 promoter reveals the implication of Ras/ERK pathway in tumor stem-like hallmarks. Mol Cancer 9: 39, 2010.
38. Takahashi K and Yamanaka S: Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126: 663-676, 2006. (Pubitemid 44233629)
39. Chen YC, Hsu HS, Chen YW, et al: Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS One 3: e2637, 2008.
40. Tabu K, Sasai K, Kimura T, et al: Promoter hypomethylation regulates CD133 expression in human gliomas. Cell Res 18: 1037-1046, 2008.
41. Yi JM, Tsai HC, Glöckner SC, et al: Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. Cancer Res 68: 8094-8103, 2008.
42. You H, Ding W and Rountree CB: Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factorbeta. Hepatology 51: 1635-1644, 2010.